We describe here several properties of a conformationally sensitive epitope common to the Moloney (M) and Rauscher (R) murine leukemia virus (MLV) gp70 family of glycoproteins, e.g., M-MLV gp70 and R-MLV gp71. This epitope was not detected by western blotting or by enzyme-linked immunosorbent assay experiments with three different lots of polyclonal R-MLV gp69/71 sera. However, it was detected when a specific monoclonal antibody, R47, was used in western blotting or immuno-dot-blotting experiments with the two viruses. R47 maps to a central 14-kd segment on R-MLV gp71 which spans an important structural domain, namely, that corresponding to the recombination site between ecotropic and endogenous envelope glycoprotein-coding sequences. Analysis of the western as well as dot blots developed with the R47 monoclonal antibody showed that about a 25-fold higher affinity for the epitope existed on R-MLV gp71, relative to M-MLV gp70. It thus appears that R-MLV and M-MLV gp70, although very closely related both structurally and serologically, are conformationally distinct in one domain, namely, the site of recombination between ecotropic and endogenous gp70-coding sequences.

Keywords:
Moloney murine leukemia virus, Envelope glycoprotein, gp70 epitope, Western blotting, Monoclonal antibody
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.